The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2

被引:929
作者
Gutmann, DH
Aylsworth, A
Carey, JC
Korf, B
Marks, J
Pyeritz, RE
Rubenstein, A
Viskochil, D
机构
[1] UNIV N CAROLINA, CHAPEL HILL, NC USA
[2] UNIV UTAH, SALT LAKE CITY, UT USA
[3] BOSTON CHILDRENS HOSP, BOSTON, MA USA
[4] SARAH LAWRENCE COLL, BRONXVILLE, NY 10708 USA
[5] ALLEGHENY UNIV HLTH SCI, PITTSBURGH, PA USA
[6] MT SINAI SCH MED, NEW YORK, NY USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1997年 / 278卷 / 01期
关键词
D O I
10.1001/jama.278.1.51
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-Neurofibromatosis 1 and neurofibromatosis 2 are autosomal dominant genetic disorders in which affected individuals develop both benign and malignant tumors at an increased frequency, Since the original National Institutes of Health Consensus Development Conference in 1987, there has been significant progress toward a more complete understanding of the molecular bases for neurofibromatosis 1 and neurofibromatosis 2. Our objective was to determine the diagnostic criteria for neurofibromatosis 1 and neurofibromatosis 2, recommendations for the care of patients and their families at diagnosis and during routine follow-up, and the role of DNA diagnostic testing in the evaluation of these disorders, Data Sources.-Published reports from 1966 through 1996 obtained by MEDLINE search and studies presented at national and international meetings. Study Selection.-All studies were reviewed and analyzed by consensus from multiple authors. Data Extraction.-Peer-reviewed published data were critically evaluated by independent extraction by multiple authors. Data Synthesis.-The main results of the review were qualitative and were reviewed by neurofibromatosis clinical directors worldwide through an Internet Web site. Conclusions.-On the basis of the information presented in this review, we propose a comprehensive approach to the diagnosis and treatment of individuals with neurofibromatosis 1 and neurofibromatosis 2.
引用
收藏
页码:51 / 57
页数:7
相关论文
共 67 条
[1]   FAMILIAL CAFE AU LAIT SPOTS - A VARIANT OF NEUROFIBROMATOSIS TYPE-1 [J].
ABELIOVICH, D ;
GELMANKOHAN, Z ;
SILVERSTEIN, S ;
LERER, I ;
CHEMKE, J ;
MERIN, S ;
ZLOTOGORA, J .
JOURNAL OF MEDICAL GENETICS, 1995, 32 (12) :985-986
[2]  
AHLBOM BE, 1995, CLIN GENET, V48, P85
[3]   WATSON SYNDROME - IS IT A SUBTYPE OF TYPE-1 NEUROFIBROMATOSIS [J].
ALLANSON, JE ;
UPADHYAYA, M ;
WATSON, GH ;
PARTINGTON, M ;
MACKENZIE, A ;
LAHEY, D ;
MACLEOD, H ;
SARFARAZI, M ;
BROADHEAD, W ;
HARPER, PS ;
HUSON, SM .
JOURNAL OF MEDICAL GENETICS, 1991, 28 (11) :752-756
[4]   Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2 [J].
Abaza, MM ;
Makariou, E ;
Armstrong, M ;
Lalwani, AK .
LARYNGOSCOPE, 1996, 106 (06) :694-699
[5]   FAMILIAL MULTIPLE CAFE AU LAIT SPOTS [J].
ARNSMEIER, SL ;
RICCARDI, VM ;
PALLER, AS .
ARCHIVES OF DERMATOLOGY, 1994, 130 (11) :1425-1426
[6]   NEUROFIBROMATOSIS AND CANCER [J].
BADER, JL .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1986, 486 :57-65
[7]  
BASER M, 1996, 1996 FASEB SUMM RES
[8]   GERMLINE MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 TUMOR-SUPPRESSOR GENE [J].
BOURN, D ;
CARTER, SA ;
MASON, S ;
EVANS, DGR ;
STRACHAN, T .
HUMAN MOLECULAR GENETICS, 1994, 3 (05) :813-816
[9]  
BRIGGS RJS, 1994, ARCH OTOLARYNGOL, V120, P1307
[10]   A MAJOR SEGMENT OF THE NEUROFIBROMATOSIS TYPE-1 GENE - CDNA SEQUENCE, GENOMIC STRUCTURE, AND POINT MUTATIONS [J].
CAWTHON, RM ;
WEISS, R ;
XU, GF ;
VISKOCHIL, D ;
CULVER, M ;
STEVENS, J ;
ROBERTSON, M ;
DUNN, D ;
GESTELAND, R ;
OCONNELL, P ;
WHITE, R .
CELL, 1990, 62 (01) :193-201